Prevalence and Risk Factors of NSAID-Induced Respiratory Reactions Among Asthmatic Patients: A Cross-Sectional Study in Zawia City, Libya.
DOI:
https://doi.org/10.54361/LJMR.19.2.47Keywords:
NSAIDs, asthma, respiratory reactions, AERD, Libya, risk factorsAbstract
Background: Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed for managing pain and inflammation. However, they may provoke respiratory reactions in asthmatic patients, with limited data available from Libya. Objectives: This study aims to assess the prevalence, patterns, and risk factors associated with NSAID-related respiratory reactions among asthmatic patients in Zawia City, Libya.Material and Methods: A cross-sectional study was conducted involving 158 asthmatic patients. Participants completed a structured questionnaire that collected data on demographics, comorbidities, NSAID usage, and respiratory symptoms. Statistical analyses were performed using chi-square tests and logistic regression. Results: Among the participants, 91.8% reported NSAID use, with 64% experiencing shortness of breath following consumption. The frequency of NSAID use, along with comorbid conditions such as rheumatoid arthritis and heart disease, was significantly associated with an increased risk of respiratory reactions. Conclusion: NSAID-related respiratory reactions are prevalent among asthmatic patients in Zawia City. These findings underscore the importance of patient education, clinical monitoring, and cautious NSAID prescribing to mitigate potential respiratory risks.
Downloads
References
1. Abou-Auda, H. (2019). Self-medication practices in developing countries: Patterns and implications. Journal of Public Health, 27(3), 215–223.
2. Doña, I., et al. (2020). NSAID hypersensitivity in asthma: Clinical patterns and management strategies. Allergy, 75(9), 2312–2324. https://doi.org/10.1111/all.14405
3. EMA. (2020). Pharmacovigilance report on NSAID-related respiratory events. European Medicines Agency.
4. Khalid, R., et al. (2022). Patterns of NSAID consumption in Middle Eastern populations. International Journal of Clinical Pharmacy, 44(2), 390–397. https://doi.org/10.1007/s11096-021-01341-2
5. Kowalski, M. L., Makowska, J. S., & Blanca, M. (2019). Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) – Classification, diagnosis and management. Current Treatment Options in Allergy, 6(3), 251–266. https://doi.org/10.1007/s40521-019-00200-5
6. Raj, R., et al. (2018). NSAID-induced bronchospasm: Mechanisms and risk factors. Journal of Asthma, 55(5), 475–483. https://doi.org/10.1080/02770903.2017.1365131
7. Szczeklik, A., & Nizankowska-Mogilnicka, E. (2017). Mechanisms of aspirin-induced asthma. European Respiratory Journal, 50(6), 1701163. https://doi.org/10.1183/13993003.01163-2017
8. Bachert, C., & Pawankar, R. (2021). Aspirin-exacerbated respiratory disease: Pathophysiology and management. Allergy, 76(5), 1382–1394. https://doi.org/10.1111/all.14653
9. Sánchez-Borges, M., & Woessner, K. M. (2018). NSAID-exacerbated respiratory disease (NERD): Current perspectives. Journal of Asthma and Allergy, 11, 31–37. https://doi.org/10.2147/JAA.S153595
10. Walters, K. M., Waldram, J. D., & White, A. A. (2018). Update on aspirin-exacerbated respiratory disease. Current Allergy and Asthma Reports, 18(4), 19. https://doi.org/10.1007/s11882-018-0774-1
11. Zed, P. J., & Loewen, P. S. (1999). Risk of NSAID-induced bronchospasm in patients with asthma. Drug Safety, 20(6), 527–538. https://doi.org/10.2165/00002018-199920060-00005
12. Laidlaw, T. M., & Cahill, K. N. (2017). Current knowledge and management of aspirin-exacerbated respiratory disease. Journal of Allergy and Clinical Immunology: In Practice, 5(3), 537–545. https://doi.org/10.1016/j.jaip.2017.01.018
13. White, A. A., Stevenson, D. D., & Simon, R. A. (2022). NSAID-exacerbated respiratory disease: 2022 update on pathogenesis and management. Annals of Allergy, Asthma & Immunology, 128(5), 517–526. https://doi.org/10.1016/j.anai.2022.02.008
14. World Health Organization (WHO). (2023). Asthma fact sheet. Retrieved from https://www.who.int/news-room/fact-sheets/detail/asthma
15. Vally, H., & Thien, F. C. K. (2011). Salicylates in foods. Journal of Clinical Pharmacology, 51(5), 553–558. https://doi.org/10.1177/0091270010368551
16. Rajan, J. P., Wineinger, N. E., Stevenson, D. D., & White, A. A. (2015). Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature. Journal of Allergy and Clinical Immunology, 135(3), 676–681.e1. https://doi.org/10.1016/j.jaci.2014.08.020
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Abdulhakim Naffati, Fateh Mostafa Alsalami, Fathi Muftahi Naser , Rabab Almabrouk Salih, Emhamed Boras, Nasrien Elfarrah (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Open Access Policy
Libyan journal of medical Research (LJMR).is an open journal, therefore there are no fees required for downloading any publication from the journal website by authors, readers, and institution.
The journal applies the license of CC BY (a Creative Commons Attribution 4.0 International license). This license allows authors to keep ownership f the copyright of their papers. But this license permits any user to download , print out, extract, reuse, archive, and distribute the article, so long as appropriate credit is given to the authors and the source of the work.
The license ensures that the article will be available as widely as possible and that the article can be included in any scientific archive.
Editorial Policy
The publication of an article in a peer reviewed journal is an essential model for Libyan journal of medical Research (LJMR). It is necessary to agree upon standards of expected ethical behavior for all parties involved in the act of publishing: the author, the journal editorial, the peer reviewer and the publisher.
Any manuscript or substantial parts of it, submitted to the journal must not be under consideration by any other journal. In general, the manuscript should not have already been published in any journal or other citable form, although it may have been deposited on a preprint server. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.
Authorship Policy
The manuscript authorship should be limited to those who have made a significant contribution and intellectual input to the research submitted to the journal, including design, performance, interpretation of the reported study, and writing the manuscript. All those who have made significant contributions should be listed as co-authors.
Others who have participated in certain substantive aspects of the manuscript but without intellectual input should only be recognized in the acknowledgements section of the manuscript. Also, one of the authors should be selected as the corresponding author to communicate with the journal and approve the final version of the manuscript for publication in the LJMR.
Peer-review Policy
- All the manuscripts submitted to LJMR will be subjected to the double-blinded peer-review process;
- The manuscript will be reviewed by two suitable experts in the respective subject area.
- Reports of all the reviewers will be considered while deciding on acceptance/revision or rejection of a manuscript.
- Editor-In-Chief will make the final decision, based on the reviewer’s comments.
- Editor-In-Chief can ask one or more advisory board members for their suggestions upon a manuscript, before making the final decision.
- Associate editor and review editors provide administrative support to maintain the integrity of the peer-review process.
- In case, authors challenge the editor’s negative decision with suitable arguments, the manuscript can be sent to one more reviewer and the final decision will be made based upon his recommendations.
